Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma

Wang,Peng; Sheng,Lili; Wang,Guoxiang; Wang,Heping; Huang,Xinyu; Yan,Xiaoxing; Yang,Xiaohua; Pei,Renguang

doi:10.3892/mco.2014.239

Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma

Authors:
- Peng Wang
- Lili Sheng
- Guoxiang Wang
- Heping Wang
- Xinyu Huang
- Xiaoxing Yan
- Xiaohua Yang
- Renguang Pei
View Affiliations

Affiliations: Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Medical Oncology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Interventional Therapy, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: January 7, 2014 https://doi.org/10.3892/mco.2014.239
Pages: 203-206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. only a minority of HCC patients benefit from curative therapies, such as surgical resection, liver transplantation, or percutaneous treatment, since the majority of HCCs are diagnosed at intermediate or advanced stages. To determine whether transarterial chemoembolization (TACE) affects survival in patients with unresectable HCC, we conducted a case-controlled study, investigating 129 patients diagnosed with intermediate- or advanced‑stage HCC, classified according to the Barcelona Clinic Liver Cancer staging system. Of these 129 patients, 102 received TACE and 27 received symptomatic treatment alone. The primary follow-up endpoint was survival. The association of TACE with survival was estimated with the Kaplan-Meier method. survival was significantly higher in the chemoembolization group compared to that in the symptomatic treatment group. The estimated 1-, 2- and 3-year survival rates were 61.8, 34.0 and 24.3% for the chemoembolization group and 51.9, 9.9 and 0% for the symptomatic treatment group (P<0.001). TACE was shown to significantly improve survival and is an effective form of treatment for patients with unresectable HCC.

View Figures

View References

1	Yang JD and Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
3	Bruix J, Sala M and Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology. 127:S179–S188. 2004. View Article : Google Scholar : PubMed/NCBI
4	Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 11:181–184. 1990. View Article : Google Scholar : PubMed/NCBI
5	Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID and Terblanche J: Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 34:1598–1600. 1993. View Article : Google Scholar : PubMed/NCBI
6	No authors listed. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med. 332:1256–1261. 1995. View Article : Google Scholar : PubMed/NCBI
7	Llovet JM, Real MI, Montana X, et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar
8	Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bruix J and Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 35:519–524. 2002. View Article : Google Scholar
11	Zhu AX: Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 17:1247–1256. 2010. View Article : Google Scholar : PubMed/NCBI
12	Trevisani F, De Notariis S, Rossi C and Bernardi M: Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 32:383–389. 2001. View Article : Google Scholar : PubMed/NCBI
13	Lau WY, Yu SC, Lai EC and Leung TW: Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 202:155–168. 2006. View Article : Google Scholar : PubMed/NCBI
14	Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI
15	Simonetti RG, Liberati A, Angiolini C and Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 8:117–136. 1997. View Article : Google Scholar : PubMed/NCBI
16	Mathurin P, Rixe O, Carbonell N, et al: Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther. 12:111–126. 1998. View Article : Google Scholar : PubMed/NCBI
17	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar
18	Camma C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 224:47–54. 2002. View Article : Google Scholar : PubMed/NCBI
19	Chin PL, Chu DZ, Clarke KG, Odom-Maryon T, Yen Y and Wagman LD: Ethnic differences in the behavior of hepatocellular carcinoma. Cancer. 85:1931–1936. 1999. View Article : Google Scholar
20	Harrison LE, Reichman T, Koneru B, et al: Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg. 139:992–996. 2004. View Article : Google Scholar : PubMed/NCBI
21	Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M and Manenti F: Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 32:233–238. 2000.PubMed/NCBI
22	Ganne-Carrie N and Trinchet JC: Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 16:275–281. 2004. View Article : Google Scholar